GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Net Income From Continuing Operations

GeneTether Therapeutics (XCNQ:GTTX) Net Income From Continuing Operations : C$-0.93 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. GeneTether Therapeutics's net income from continuing operations for the three months ended in Dec. 2023 was C$-0.42 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was C$-0.93 Mil.

GeneTether Therapeutics Net Income From Continuing Operations Historical Data

The historical data trend for GeneTether Therapeutics's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Net Income From Continuing Operations Chart

GeneTether Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Income From Continuing Operations
-0.09 -2.10 -2.33 -0.92

GeneTether Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.28 -0.19 -0.04 -0.42

GeneTether Therapeutics Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneTether Therapeutics (XCNQ:GTTX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Net Income From Continuing Operations
Comparable Companies
TSXV:IBO XCNQ:MOOD XCNQ:ENBI XCNQ:AGN XCNQ:ABRT XCNQ:CURE XCNQ:MYND TSXV:PSYB TSXV:VXL XCNQ:HAVN OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, V1Y 2B3
Website
https://www.genetether.com
GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin.

GeneTether Therapeutics (XCNQ:GTTX) Headlines

No Headlines